A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
- Conditions
- Breast Cancer
- Registration Number
- NCT00063102
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 40
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Objective Response Rate in subjects with Breast cancer 1 year
- Secondary Outcome Measures
Name Time Method Time to Tumor Progression (TTP) 1 year Survival 2 years Toxicities associated with treatment administration 1 year
Trial Locations
- Locations (8)
Oncology-Hematology Group of South Florida
🇺🇸Miami, Florida, United States
Clinical Research Network, Inc.
🇺🇸Plantation, Florida, United States
Georgia Cancer Specialists
🇺🇸Atlanta, Georgia, United States
Northwestern University Medical School Division of Hematology/Oncology
🇺🇸Chicago, Illinois, United States
Indiana University Cancer Center Section of of Hemtology/Oncology Indiana Cancer Pavilion
🇺🇸Indianapolis, Indiana, United States
Northern Indiana Cancer Research Consortium
🇺🇸South Bend, Indiana, United States
Oncology & Hemotology Associates of Kansas City, PA
🇺🇸Kansas City, Missouri, United States
Texas Oncology
🇺🇸Dallas, Texas, United States
Oncology-Hematology Group of South Florida🇺🇸Miami, Florida, United States